Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer.

Autor:	Jungles KM; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, United States.; Department of Pharmacology, University of Michigan, Ann Arbor, MI, United States., Holcomb EA; Graduate Program in Immunology, University of Michigan Medical School, Ann Arbor, MI, United States., Pearson AN; Graduate Program in Immunology, University of Michigan Medical School, Ann Arbor, MI, United States., Jungles KR; Department of Biology, Saint Mary's College, Notre Dame, IN, United States., Bishop CR; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States., Pierce LJ; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, United States., Green MD; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, United States.; Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, United States.; Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI, United States., Speers CW; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, United States.; Department of Radiation Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, OH, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2022 Oct 26; Vol. 12, pp. 1022542. Date of Electronic Publication: 2022 Oct 26 (Print Publication: 2022).
DOI:	10.3389/fonc.2022.1022542
Abstrakt:	Breast cancer is the most prevalent non-skin cancer diagnosed in females and developing novel therapeutic strategies to improve patient outcomes is crucial. The immune system plays an integral role in the body's response to breast cancer and modulating this immune response through immunotherapy is a promising therapeutic option. Although immune checkpoint inhibitors were recently approved for the treatment of breast cancer patients, not all patients respond to immune checkpoint inhibitors as a monotherapy, highlighting the need to better understand the biology underlying patient response. Additionally, as radiotherapy is a critical component of breast cancer treatment, understanding the interplay of radiation and immune checkpoint inhibitors will be vital as recent studies suggest that combined therapies may induce synergistic effects in preclinical models of breast cancer. This review will discuss the mechanisms supporting combined approaches with radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. Moreover, this review will analyze the current clinical trials examining combined approaches of radiotherapy, immunotherapy, chemotherapy, and targeted therapy. Finally, this review will evaluate data regarding treatment tolerance and potential biomarkers for these emerging therapies aimed at improving breast cancer outcomes. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Jungles, Holcomb, Pearson, Jungles, Bishop, Pierce, Green and Speers.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu